Jaguar Health pounces on the European market with an investment in Milan


investment overview

Investor company description

Jaguar Health, Inc. is a US-based company focused on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. 

Chief among these pharmaceuticals is Jaguar’s novel proprietary drug, crofelemer, which is approved in the U.S. for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy.

Investment description

On March 2021, the company set up its first European Subsidiary in Milan (Napo EU) to move forward with Crofelemer’s EMA approval process in Europe for the treatment of the rapidly emerging “longhauler” health issues in COVID-19 recovery patients. 

The “Invest In Italy” team, including the Italian Trade Agency, its office in San Francisco and Invitalia, together with the local investment agency Milano & Partners, supported the establishment of Napo EU in Milan by providing several business services

Napo EU has the exclusive licensing rights to produce and distribute Crofelemer in Europe, lead the clinical trials and approval process, scale production thanks to a Contract Manufacturing agreement with a local Italian company, and coordinate Business Development.


Accompanying facilities required:

- Support for location scouting

- Support for research and recruitment

- Legal entity set-up and SPAC listing assessment

- Engagement with the local financial community


Press Release

Jaguar Health Announces Incorporation of Napo EU Subsidiary in Italy

website icon


Jaguar Health